mibefradil has been researched along with flunarizine in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Back, SK; Choo, HY; Kam, YL; Na, HS; Rhee, HK; Rhim, H | 1 |
| Baek, du J; Cho, YS; Choi, YH; Lee, JK; Min, SJ; Pae, AN; Seo, SH | 1 |
| Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
| Cho, YS; Hwang, EM; Jung, SY; Lim, SM; Min, SJ; Pae, AN; Park, KD; Viswanath, AN | 1 |
| Haynes, J; Li, M; Obiako, BO; Stevens, T; Stubbs, JR; Taylor, JT; Wu, S | 1 |
| Akaike, N; Kim, CJ; Min, BI; Ogawa, S; Shin, MC; Tanaka, E | 1 |
| Amobi, N; Guillebaud, J; Smith, CH | 1 |
| Capuano, V; Ferron, L; Renaud, JF; Ruchon, Y; Sankhe, S | 1 |
9 other study(ies) available for mibefradil and flunarizine
| Article | Year |
|---|---|
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Synthesis and T-type calcium channel blocking activity of novel diphenylpiperazine compounds, and evaluation of in vivo analgesic activity.
Topics: Analgesics; Animals; Calcium Channels, T-Type; Humans; Neuralgia; Pain Measurement; Piperazines; Rats | 2010 |
Facile synthesis and biological evaluation of 3,3-diphenylpropanoyl piperazines as T-type calcium channel blockers.
Topics: Benzhydryl Compounds; Calcium Channel Blockers; Calcium Channels, T-Type; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; High-Throughput Screening Assays; Humans; Piperazines; Structure-Activity Relationship | 2011 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Identification of the first in silico-designed TREK1 antagonists that block channel currents dose dependently.
Topics: Animals; Computer Simulation; Crystallography, X-Ray; Dose-Response Relationship, Drug; HEK293 Cells; Humans; Mice; Mice, Knockout; Molecular Docking Simulation; Potassium Channels, Tandem Pore Domain | 2016 |
Cav3.1 (alpha1G) T-type Ca2+ channels mediate vaso-occlusion of sickled erythrocytes in lung microcirculation.
Topics: Amino Acid Sequence; Anemia, Sickle Cell; Animals; Calcium; Calcium Channel Blockers; Calcium Channels, T-Type; Cell Adhesion; Cells, Cultured; Dose-Response Relationship, Drug; Electric Stimulation; Endothelium, Vascular; Erythrocytes, Abnormal; Flunarizine; Lung; Membrane Potentials; Mibefradil; Microcirculation; Molecular Sequence Data; Neurotoxins; Nickel; Pimozide; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA; Scorpion Venoms; Sequence Homology, Amino Acid | 2003 |
A selective T-type Ca2+ channel blocker R(-) efonidipine.
Topics: Animals; Barium; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Channels, T-Type; Dihydropyridines; Dose-Response Relationship, Drug; Flunarizine; Mibefradil; Nitrophenols; Nystatin; Organophosphorus Compounds; Patch-Clamp Techniques; Potassium Channels, Calcium-Activated; Pyramidal Cells; Rats; Rats, Wistar; Sodium Channels | 2008 |
Comparative effects of T-type and L-type Ca(2+)-antagonists against noradrenaline-induced contractions of human vas deferens.
Topics: Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Flunarizine; Humans; Male; Mibefradil; Muscle Contraction; Muscle, Smooth; Nifedipine; Norepinephrine; Pyrroles; Vas Deferens | 2010 |
T-type Ca²⁺ signalling downregulates MEK1/2 phosphorylation and cross-talk with the RAAS transcriptional response in cardiac myocytes.
Topics: Animals; Calcium Signaling; Flunarizine; Fluoxetine; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mibefradil; Mifepristone; Mineralocorticoid Receptor Antagonists; Myocytes, Cardiac; Nifedipine; Phosphorylation; Rats; Rats, Wistar; Receptors, Glucocorticoid; Renin-Angiotensin System; Spironolactone | 2012 |